- Home
- HEPS vs PCRX Comparison
HEPS vs PCRX Comparison
Compare HEPS & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HEPS | PCRX |
|---|---|---|
| Founded | 2000 | 2006 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 948.0M | 1.0B |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | HEPS | PCRX |
|---|---|---|
| Price | $2.84 | $24.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.07 | ★ $30.25 |
| AVG Volume (30 Days) | 229.2K | ★ 422.6K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | $41.29 | $6.78 |
| Revenue Next Year | $27.99 | $8.54 |
| P/E Ratio | ★ N/A | $154.13 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $2.15 | $18.80 |
| 52 Week High | $3.30 | $27.99 |
Technical Indicators
Market Signals| Indicator | HEPS | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 57.96 | 62.94 |
| Support Level | $2.53 | $20.56 |
| Resistance Level | $2.85 | $25.23 |
| Average True Range (ATR) | 0.07 | 0.78 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 66.13 | 84.95 |
Price Performance
Historical ComparisonAbout HEPS D-Market Electronic Services & Trading
D-MARKET Electronic Services & Trading offers an e-commerce platform in Turkey and the surrounding region. The company is comprised of one reportable segment, namely e-commerce operations. The Group derives revenue from the sales of goods, marketplace revenues and other revenues.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.